A composition of a locally acting androgen receptor antagonist and its application
CN117205148BActive Publication Date: 2026-05-26SIJU BIOMEDICAL CO LTD
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- SIJU BIOMEDICAL CO LTD
- Filing Date
- 2022-04-29
- Publication Date
- 2026-05-26
AI Technical Summary
Technical Problem
Existing medications for treating androgenetic alopecia, such as minoxidil and finasteride, have side effects and limitations, necessitating the development of a safer and more effective treatment.
Method used
A composition containing sec-butyl 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioimidazolin-1-yl)-2-fluorobenzoate is provided for the treatment of androgenetic alopecia by topically inhibiting the production of dihydrotestosterone or antagonizing its effect on androgen receptors in hair follicles.
Benefits of technology
This composition can effectively inhibit the production of dihydrotestosterone, reduce hair loss, reduce side effects, provide a stable high-concentration solution, and improve treatment efficacy.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure CN117205148B_ABST
Abstract
This invention discloses a locally acting androgen receptor antagonist composition and its application. The composition is a solution containing 0.1% to 7.5% g / mL of sec-butyl 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioimidazolin-1-yl)-2-fluorobenzoate. This invention enables the preparation of high-concentration solutions of sec-butyl 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioimidazolin-1-yl)-2-fluorobenzoate and its stereoisomers, and increases their stability in dissolution.
Need to check novelty before this filing date? Find Prior Art